An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization

Vaccine

Volumn 28, Issue 8, 2010, Pages 1952-1961

  Lemiale, Franck ^a   Asefa, Benyam ^a   Ye, Delia ^a   Chen, Christopher ^a   Korokhov, Nikolay ^a   Humeau, Laurent ^a  

^a VIRxSYS Corporation   (United States)

Author keywords

HIV; Lentivirus; Vaccine

Indexed keywords

CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VRX 1023;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VACCINATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LENTIVIRUS; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 76949095061     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.089     Document Type: Article

References (47)

1. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
2. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10 (2004) 806-810
3. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
4. Mcmichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
5. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205 (2008) 63-77
6. Johnston M.I., and Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 356 (2007) 2073-2081
7. Perreau M., Pantaleo G., and Kremer E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205 12 (2008) 2717-2725
8. Liu J., O'brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457 (2009) 87-91
9. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 318 (2007) 1048-1049
10. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 (2008) 7-12
11. Levine B.L., Humeau L., Boyer J., Macgregor R.-R., Rebello T., Xiaobin L., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS 103 (2006) 5
12. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
13. Esslinger C., Romero P., and Macdonald H.R. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 13 (2002) 1091-1100
14. He Y., Zhang J., Donahue C., and Falo Jr. L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24 (2006) 643-656
15. Lu X., Humeau L., Slepushkin V., Binder G., Yu Q., Slepushkina T., et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 6 (2004) 963-973
16. Vladimir Slepushkin, Nancy Chang R., Cohen Y.G., Bing Jiang E., Deausen D., Berlinger G., et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. J Bioprocess (2003) 89-95
17. Blazevic V., Mannik A., Malm M., Sikut R., Valtavaara M., Toots U., et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses 22 (2006) 667-677
18. Huang Y., Kong W.P., and Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75 (2001) 4947-4951
19. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77 (2003) 10078-10087
20. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., and Gall J.G. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25 (2007) 2074-2084
21. Reynolds M.R., Weiler A.M., Weisgrau K.L., Piaskowski S.M., Furlott J.R., Weinfurter J.T., et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205 11 (2008) 2537-2550
22. Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., and Ruprecht R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267 (1995) 1820-1825
23. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5 (1999) 194-203
24. Lubeck M.D., Natuk R.J., Chengalvala M., Chanda P.K., Murthy K.K., Murthy S., et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 10 (1994) 1443-1449
25. Gherardi M.M., Perez-Jimenez E., Najera J.L., and Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172 (2004) 6209-6220
26. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004) 2286-2294
27. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
28. LA Montagne J.R., and Fauci A.S. Intradermal influenza vaccination-can less be more?. N Engl J Med 351 (2004) 2330-2332
29. Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Levy F., et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111 (2003) 1673-1681
30. Dullaers M., and Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 8 (2006) 3-17
31. He Y., Zhang J.M.I.Z., Robbins P., and Falo Jr. L.D. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174 (2005) 3808-3817
32. Hachiya A., Sriwiriyanont P., Patel A., Saito N., Ohuchi A., Kitahara T., et al. Gene transfer in human skin with different pseudotyped HIV-based vectors. Gene Ther 14 (2007) 648-656
33. He Y., and Falo Jr. L.D. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 9 (2007) 439-446
34. Lopes L., Dewannieux M., Gileadi U., Bailey R., Ikeda Y., Whittaker C., et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 82 (2008) 86-95
35. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
36. Salerno-Goncalves R., and Sztein M.B. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol 14 (2006) 536-542
37. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73 (1999) 7524-7532
38. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
39. Robinson H.L., and Weinhold K.J. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. J Infect Dis 194 (2006) 1625-1627
40. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 3 (2009) 293-299
41. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 321 (2008) 530-532
42. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18 (2004) 1213-1216
43. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 (2004) 351-357
44. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78 (2004) 2666-2673
45. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 (2005) 7179-7185
46. Palmowski M.J., Lopes L., Ikeda Y., Salio M., Cerundolo V., and Collins M.K. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 172 (2004) 1582-1587
47. Lemiale F., and Korokhov N. Lentiviral vectors for HIV disease prevention and treatment. Vaccine 27 25-26 (2009) 3443-3449